产品管线

RESEARCH & DEVELOPMENT

Program

Target

Development Strategy

Indications

PCC

IND

Phase I

Phase II

Phase III

Clinical Study Site

TY-9591 3rd generation EGFR-TKI（不显示1）

EGFR

Mono

NSCLC (the first line)

TY-9591

EGFR

Mono

EGFR lung cancer with brain metastasis

TY-9591 3rd generation EGFR-TKI（不显示2）

EGFR

+ CDK4/6 inhibitor

EGFR resistance

TY-302

CDK4/6

+ Toremifene

Breast cancer

TY-302（不显示1）

CDK4/6

+ Abiraterone

Prostatic cancer

TY-2136b

ROS1/NTRK/ALK

Mono

ROS1/ALK resistant NSCLC

,

TY-2136b（不显示）

ROS1/NTRK/ALK

Mono

NTRK fusion positive cancer

,

TY-1091

RET

Mono

RET-Fusion NSCLC

,

TY-1091(不显示）

RET

Mono

RET-Mutation MTC

,

TY-2699a

CDK7

Mono or combo

TNBC, ER+HER2-BC, PDAC

,

TY-0540

CDK2/4/6

Mono or combo

BC, Prostatic cancer, Pancreatic cancer

,

TY-4028

EGFR/HER2 Exon 20ins

Mono

Lung cancer

,

TY-1054

YAP/TEAD

Mono or combo

Solid tumor

,

TY-XXXX

CDK

Mono or combo

Solid tumor

TY-XXXX

Not Disclosed

Mono or combo

Solid tumor

PROTAC

Not Disclosed

Mono

Solid tumor